William Blair initiated coverage of Viridian Therapeutics (VRDN) with an Outperform rating and $47 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics initiated with a Buy at Truist
- Promising Developments and Market Potential Drive Buy Rating for Viridian Therapeutics
- Viridian Therapeutics Advances Toward Profitability with Strategic Moves
- Viridian Therapeutics price target raised to $45 from $41 at RBC Capital
- Viridian Therapeutics price target raised to $40 from $30 at Goldman Sachs